Intravenous GP-1-531 adenosine regulating agent: Began Phase I trial in the U.K. of the intravenous form owned by ARAM; the oral form, owned by GNSA, willl be t

Gensia Inc. (GNSA), San Diego

Read the full 56 word article

How to gain access

Continue reading with a
two-week free trial.